Marengo Therapeutics to Present Promising Results of Invikafusp Alfa at SITC 2025 Meeting
Marengo Therapeutics, Inc., a clinical-stage biotechnology firm, is pushing the boundaries of precision immunotherapy in oncology, planning to unveil key findings at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. This event is scheduled for November 5–9, 2025, in National Harbor, Maryland, and Marengo will share results highlighting the initial monotherapy activity of Invikafusp Alfa.
At this notable conference, Marengo will present Phase 2 preliminary results from the STARt-001 clinical trial, which zeroes in on using Invikafusp Alfa as a treatment for tissue-agnostic, tumor mutational burden-high (TMB-H) advanced cancers. The findings from this trial are significant as they suggest that Invikafusp Alfa may uniquely activate specific T cell subsets, potentially bolstering anti-tumor immunity across various solid tumors.
Alongside the presentation on Invikafusp Alfa, Marengo will highlight findings from their innovative TriSTAR T cell engager platform and four preliminary studies done in collaboration with the National Cancer Institute (NCI). These analyses explore rational combinations of Invikafusp Alfa with established treatment modalities, indicating an integrated approach to cancer treatment.
A clinical-stage biotechnology company, Marengo is at the forefront of developing novel TCR-targeting antibodies intended to modulate T cell subsets specifically. The goal is to create therapies that offer enduring protection against cancer and autoimmune diseases. The team comprises dedicated scientists focusing on immunology and oncology, leveraging proprietary platforms such as Selective T Cell Activation Repertoire (STAR), Trispecific T Cell Engager (Tri-STAR), and T cell Depletor (MSTAR). Their mission is clear: to target the appropriate T cells for the correct patients, ultimately enabling each person's immune system to conquer cancer and autoimmune diseases. More information can be found at marengotx.com.
Marengo’s STAR™ Platform is a groundbreaking antibody-fusion technology that empowers precise targeting of T cell responses. By utilizing a library of antibodies focused on germline-encoded variable Vβ regions of the TCR, this approach cultivates a durable anti-tumor response through innovative mechanisms that promote T cell activation.
Invikafusp Alfa (STAR0602) stands at the pinnacle of Marengo’s STAR™ platform as the lead candidate meticulously designed to stimulate a widespread Vβ T cell subset found in various cancers. It combines a novel approach to TCR activation with an integrated T cell co-stimulatory signal, significantly enhancing anti-tumor immunity and paving the way for effective tumor clearance.
The STARt-001 clinical trial is a comprehensive global Phase 1/2 study that examines the safety, tolerability, and efficacy of invikafusp alfa as a standalone treatment for patients with advanced antigen-rich solid tumors, including those resistant to PD-1 therapies. This trial encompasses two parts: Phase 1 emphasizes dose escalation, while Phase 2 focuses on dose expansion. For further details, interested individuals can check clinicaltrials.gov (Identifier NCT05592626) or reach out to NCI’s informational resource via a toll-free number.
In the ever-evolving landscape of oncological treatments, Marengo Therapeutics continues to innovate and inspire hope, aiming to provide groundbreaking therapies that could redefine patient care and treatment outcomes in the battle against cancer.
At this notable conference, Marengo will present Phase 2 preliminary results from the STARt-001 clinical trial, which zeroes in on using Invikafusp Alfa as a treatment for tissue-agnostic, tumor mutational burden-high (TMB-H) advanced cancers. The findings from this trial are significant as they suggest that Invikafusp Alfa may uniquely activate specific T cell subsets, potentially bolstering anti-tumor immunity across various solid tumors.
Presentation Details
- - Title: Initial Monotherapy Clinical Activity of Invikafusp Alfa, a First-in-Class TCR β-Chain-Targeted Bifunctional Antibody, in Tissue-Agnostic, TMB-H Patients from STARt-001, a Phase 1/2 Trial
- - Conference: SITC Annual Meeting 2025
- - Abstract Number: LBA1316
- - Session Title: Clinical Oral Abstract Session 1
- - Session Date and Time: November 7, 2025, at 11:30 AM ET
- - Presenter: Dr. Aurélien Marabelle of Gustave Roussy Cancer Center, France
Alongside the presentation on Invikafusp Alfa, Marengo will highlight findings from their innovative TriSTAR T cell engager platform and four preliminary studies done in collaboration with the National Cancer Institute (NCI). These analyses explore rational combinations of Invikafusp Alfa with established treatment modalities, indicating an integrated approach to cancer treatment.
About Marengo Therapeutics
A clinical-stage biotechnology company, Marengo is at the forefront of developing novel TCR-targeting antibodies intended to modulate T cell subsets specifically. The goal is to create therapies that offer enduring protection against cancer and autoimmune diseases. The team comprises dedicated scientists focusing on immunology and oncology, leveraging proprietary platforms such as Selective T Cell Activation Repertoire (STAR), Trispecific T Cell Engager (Tri-STAR), and T cell Depletor (MSTAR). Their mission is clear: to target the appropriate T cells for the correct patients, ultimately enabling each person's immune system to conquer cancer and autoimmune diseases. More information can be found at marengotx.com.
The STAR™ Platform
Marengo’s STAR™ Platform is a groundbreaking antibody-fusion technology that empowers precise targeting of T cell responses. By utilizing a library of antibodies focused on germline-encoded variable Vβ regions of the TCR, this approach cultivates a durable anti-tumor response through innovative mechanisms that promote T cell activation.
Insight into Invikafusp Alfa (STAR0602)
Invikafusp Alfa (STAR0602) stands at the pinnacle of Marengo’s STAR™ platform as the lead candidate meticulously designed to stimulate a widespread Vβ T cell subset found in various cancers. It combines a novel approach to TCR activation with an integrated T cell co-stimulatory signal, significantly enhancing anti-tumor immunity and paving the way for effective tumor clearance.
The STARt-001 Clinical Study
The STARt-001 clinical trial is a comprehensive global Phase 1/2 study that examines the safety, tolerability, and efficacy of invikafusp alfa as a standalone treatment for patients with advanced antigen-rich solid tumors, including those resistant to PD-1 therapies. This trial encompasses two parts: Phase 1 emphasizes dose escalation, while Phase 2 focuses on dose expansion. For further details, interested individuals can check clinicaltrials.gov (Identifier NCT05592626) or reach out to NCI’s informational resource via a toll-free number.
In the ever-evolving landscape of oncological treatments, Marengo Therapeutics continues to innovate and inspire hope, aiming to provide groundbreaking therapies that could redefine patient care and treatment outcomes in the battle against cancer.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.